Clinical trials employing mebendazole for the treatment of high -
grade glioma patients which receive temozolomide and for recurrent / progressive pediatric brain tumors are in the recruiting phase.
The scientists will analyze whether blood levels of CMV in high - grade
glioma patients currently receiving standard therapies correlate with changes in blood counts, an indicator of a therapy's success or failure.
Ultimately, the Johns Hopkins investigators hope to determine whether high -
grade glioma patients should be routinely screened for CMV and if antiviral medications or treatment may have an impact on outcomes.
Johns Hopkins scientists are conducting research in high - grade
glioma patients to measure the blood levels of cytomegalovirus (CMV), a common virus that can cause severe disease in patients with weakened immune systems.
Glioma patients have follow - up MRIs to detect new brain cancers but the tests do not catch the tumors early enough to save lives.
Glioma patients can experience weakened immune systems as a result of therapies like radiation, chemotherapy and high - dose steroids used to treat their cancer.